HeartSciences Inc. (HSCS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HeartSciences Inc. on September 26, 2025, with a signature date of October 1, 2025. The filing discloses material updates regarding the company's debt obligations and equity financing activities, specifically the extension of a secured loan and progress on a Regulation A offering.
Key Financial Metrics and Capital Structure
- Debt Obligations: The company maintains a secured, non-convertible promissory note with Front Range Ventures LLC (FRV) for a principal amount of $500,000. The note accrues interest at 12% per annum, compounded annually.
- Equity Financing (Regulation A): As of October 1, 2025, the company has raised $6.7 million in gross proceeds from its Regulation A offering. This resulted in the issuance of 1,912,383 Units (consisting of Series D Preferred Stock and Warrants).
- Debt-to-Equity Conversion: The company executed a debt exchange totaling $2,105,000 ($2,060,000 principal + $45,000 accrued interest) for 597,578 shares of common stock.
- Share Count: Following the Regulation A conversions and debt exchange, there were 3,069,635 shares of common stock issued and outstanding as of October 1, 2025.
Material Changes and Agreements
Loan Extension (Item 1.01): On September 26, 2025, HeartSciences entered into Amendment No. 7 to its Loan Agreement with FRV. Key changes include:
- Extension of the maturity date to September 30, 2026.
- Requirement to pay all accrued unpaid interest as of September 30, 2025, on or before that date.
- Future accrued interest is payable on the new maturity date.
- The company retains the right to prepay the note in increments of at least $50,000, applied first to accrued interest and then to principal.
Capitalization Changes (Item 8.01): The filing details significant changes in capitalization as of October 1, 2025:
- 1,331,044 shares of Series D Preferred Stock issued via the Regulation A offering were converted into common stock.
- Reduction of unsecured promissory note liabilities through the issuance of common stock.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operational performance. The primary focus is on liquidity management through debt restructuring and capital raising. The company continues to rely on its Regulation A offering to raise funds, having secured approximately 45% of its maximum $15 million target as of the reporting date.
Investor Verification Checklist
- Verify the payment status of the accrued interest due to FRV as of September 30, 2025, to ensure no default has occurred.
- Confirm the remaining capacity and timeline for the Regulation A offering to reach the $15 million maximum.
- Review the terms of the unsecured promissory note that was partially exchanged for equity to understand remaining liabilities.
- Monitor the dilution impact of the 3,069,635 outstanding common shares relative to the company's total authorized share count.